Skip to main content
padlock icon - secure page this page is secure

Recent Clinical Aspects of Hyperprolactinemia Induced by Antipsychotics

Buy Article:

$68.00 + tax (Refund Policy)

This review will address the current understanding of the relationship between hyperprolactinemia and antipsychotic drugs. Hyperprolactinemia is a frequent but often neglected side effect of typical, but also of many atypical antipsychotics. Release of PRL from lactotrope cells is influenced by several factors, such as stress, physical and sexual activity and food assumption. PRL secretion is regulated by hypothalamic-pituitary portal system and its homeostasis is the result of a complex balance between stimulating and inhibitory factors, both endogeneous and esogeneous. The main physiological control mechanism of secretion is played by the inhibitory action of dopamine. Conversely, among stimulation factors, serotonin is probably the main modulator of PRL release. An high number of drugs may cause PRL increase too, such as drugs that reduce dopaminergic functions at SNC level, or drugs with an antagonistic action towards dopaminergic receptors and those increasing serotonergic neurotransmission. Hyperprolactinemia is one of the most frequent endocrine pathologies of the hypothalamic-pituitary axis. Antipsychotics (AP) are the most common cause of druginduced hyperprolactinemia. Not all AP have the same impact on inducing hyperprolactinemia. In this review we will focus on the subdivision of AP in ‘PRL-raising’ (stimulators) and ‘PRL-sparing’ (sparers) and on their differences in inducing hyperprolactinemia. Finally we evaluated different complications in patients with antipsychotics induced hyperprolactinemia that may cause not only short-term side effects but also important systemic long-term effects. At the end of the review we finally report the possible options of treatment considering however that at present there are no ideal therapies or evaluations, and decisions have to be made on a case by case basis.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 5HT1A; 5HT2 receptors; ACh; Amenorrhea; CNS; Cathecolamines; D2 receptors; Estrogens; Gaba; Galanin Oxytocin; Glucocorticoids; Leptin; MSH; Oligomenorrhea; Osteoporosis; Progesterone; Prolactin; Prolactin- Inibithor Factor: PIF; Serotonin; T3; TGF1; TRH VIP; amisulpride; antipsychotics; aripiprazole; cardiac valvulopathy; clozapine; hyperprolactinemia; olanzapine; omnipotin; pergolide; quetiapine; risperidone; thyrotropin-releasing hormone (TRH); tuberoinfundibular dopamine pathway; vasoactive intestinal peptide; vasopressin; versatilin; ziprasidone

Document Type: Research Article

Publication date: January 1, 2011

More about this publication?
  • Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I - IV clinical trial studies, clinical investigations at all stages of development and therapeutics.

    The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more